Author

A. Perren

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Assay:DNA methylation· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1

Frequent Co-Authors

I. Marinoni· 3 shared A. Di Domenico· 2 shared D. Horst· 2 shared E. Vassella· 2 shared K. Detjen· 2 shared M. C. Sadowski· 2 shared R. S. Maire· 2 shared A. Chouchane· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

I. Marinoni

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Unlocking the potential of miR-19b in the regulation of temozolomide response in glioblastoma patients via targeting PPP2R5E, a subunit of the protein phosphatase 2A complex

E. Kashani, K. Hlavackova, S. Haemmig, M. C. Sadowski, J. Phour, U. Baumgartner, N. Mueller-Wirth, C. Trefny, B. Sharf Den Abu Fakher, C. Nydegger, T. Maragkou, P. Schucht, A. Perren, P. Zinn, M. Luedi, , E. Vassella

This study identifies miR-19b's role in TMZ resistance in GBM by targeting PPP2R5E, showing that miR-19b attenuation enhances TMZ efficacy in cell lines and xenografts.

bioRxiv · Jan 16, 2023Cancer Biology

Patient-derived tumoroids of advanced high-grade neuroendocrine neoplasms mimic patient chemotherapy responses and guide the design of personalized combination therapies

S. L. April-Monn, K. Detjen, P. Kirchner, K. Braeutigam, M. A. Trippel, T. Grob, C. Statzer, R. S. Maire, A. Kollar, A. Chouchane, C. A. Kunze, D. Horst, M. C. Sadowski, J. Schrader, I. Marinoni, , A. Perren

The paper develops patient-derived tumoroids to predict chemotherapy responses and identify synergistic drug combinations for high-grade GEP-NEN.

bioRxiv · Dec 10, 2022 · PreprintCancer Biology

DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas (PanNECs) and pancreatic neuroendocrine tumors (PanNETs)

T. Simon, P. Riemer, K. Detjen, A. Di Domenico, F. Bormann, A. Menne, S. Khouja, N. Monje, L. H. Childs, D. Lenze, U. Leser, A. Jarosch, F. Rossner, M. Morkel, N. Bluethgen, , C. Sers

The paper uses DNA methylation analysis to distinguish high-grade PanNECs from other PanNETs, revealing an exocrine cell of origin for PanNECs.

bioRxiv · Jun 12, 2020Cancer Biology

Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression

A. Di Domenico, C. P. Pipinikas, R. S. Maire, K. Bräutigam, C. Simillion, M. S. Dettmer, E. Vassella, C. Thirlwell, A. Perren, I. Marinoni

The paper uses DNA methylation profiling to identify cell origins and progression mechanisms in PanNETs, finding distinct epigenetic clusters associated with different cell types and clinical outcomes.

bioRxiv · Apr 8, 2020Cancer Biology